(1) To determine the frequency of antibody-mediated encephalopathy in children with seizure-related or (sub)acute onset neuropsychiatric disorders. (2) To identify the target auto-antigens of selected seizure-related and (sub)acute onset…
ID
Source
Brief title
Condition
- Autoimmune disorders
- Central nervous system infections and inflammations
- Psychiatric and behavioural symptoms NEC
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
1. The characterization of new antibody-related clinical syndromes; 2. The
frequency of the individual antibody-mediated syndromes in children; 3. The
outcome of the individual antibody-mediated syndromes in children.
Secondary outcome
not applicable
Background summary
The CHANCE study aims to establish antibody associations and the autoimmune
origin of several epileptic and neuropsychiatric disorders of unknown etiology
in children, and investigate the effects of the antibodies on cell surface and
neurotransmitter synaptic receptors. Recently an expanding group of
antibody-mediated autoimmune encephalitis was discovered which associated with
seizures, status epilepticus or behavioral symptoms occurring alone or with
other symptoms. The impact of these studies has been immediate: seizure
disorders previously considered *fever-induced*, idiopathic or *possibly viral*
are defined as autoimmune and treatable, as patients recover with
immunotherapy. This work has led us to hypothesize that many acquired seizure/
neuropsychiatric disorders of unknown etiology including new-onset
seizures/status epilepticus related to encephalitis, fever-induced refractory
epileptic encephalopathy in school-age children (FIRES) and pediatric
autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS)
are mediated by antibodies affecting neurotransmitter receptors at cell surface
or synaptic sites.
Study objective
(1) To determine the frequency of antibody-mediated encephalopathy in children
with seizure-related or (sub)acute onset neuropsychiatric disorders.
(2) To identify the target auto-antigens of selected seizure-related and
(sub)acute onset neuropsychiatric disorders in children for which we have
preliminary evidence of antibodies to neuronal cell surface/synaptic proteins,
and
(3) To assess the effects of the antibodies on neurons and/or synapses in vitro
and, for the most interesting 1 or 2 antibodies/antigens, in vivo.
Study design
Observational cohort study
Study burden and risks
The study patients will have one venapunction, with negligible risks and
burden. The diseases at hand are mainly age-group specific, and as the brain
and immune system are different in adults from children the study cannot be
extrapolated from studying adults.
's Gravendijkwal 230
Rotterdam 3015 CE
NL
's Gravendijkwal 230
Rotterdam 3015 CE
NL
Listed location countries
Age
Inclusion criteria
- Age under 18 years
- Clinical profile fits one of the four groups: 1. limbic or cortical encephalitis, 2. new-onset seizures/status epilepticus without known cause, 3. acute encephalopathy with fever/inflammation-mediated status epilepticus or 4. acute-onset neuropsychiatric symptoms of basal ganglia dysfunction, like chorea .
- No known cause, like a bacteria, virus, haemorrhage, stroke, genetic cause.
Exclusion criteria
- 18 years or over
- Patient and/ or legal representative is withholding informed consent
- Patient objects after initial informed consent (see paragraph 8.3).
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL47872.078.14 |